Causes and consequences of tumour acidity and implications for treatment.

Tumour cells have a lower extracellular pH (pHe) than normal cells; this is an intrinsic feature of the tumour phenotype, caused by alterations either in acid export from the tumour cells or in clearance of extracellular acid. Low pHe benefits tumour cells because it promotes invasiveness, whereas a high intracellular pH (pHi) gives them a competitive advantage over normal cells for growth. Molecular genetic approaches have revealed hypoxia-induced coordinated upregulation of glycolysis, a potentially important mechanism for establishing the metabolic phenotype of tumours. Understanding tumour acidity opens up new opportunities for therapy.

[1]  E. T. Gawlinski,et al.  A reaction-diffusion model of cancer invasion. , 1996, Cancer research.

[2]  D. Fell Understanding the Control of Metabolism , 1996 .

[3]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[4]  J. Griffiths,et al.  Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells. , 1998, British Journal of Cancer.

[5]  K. Brindle,et al.  Effects of overexpression of phosphofructokinase on glycolysis in the yeast Saccharomyces cerevisiae. , 1992, Biochemistry.

[6]  J R Griffiths,et al.  31P-NMR investigation of solid tumours in the living rat , 1981, Bioscience reports.

[7]  I. Tannock,et al.  The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. , 1998, British Journal of Cancer.

[8]  R. Gillies,et al.  Role of Intracellular pH in Mammalian Cell Proliferation , 1992 .

[9]  I. Tannock,et al.  Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Folkman Tumor angiogenesis and tissue factor , 1996, Nature Medicine.

[11]  M. Wei,et al.  Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[13]  I. Tannock,et al.  The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects. , 1996, British Journal of Cancer.

[14]  P. Ratcliffe,et al.  Hypoxia and the regulation of gene expression. , 1998, Molecular medicine today.

[15]  J. Shirlaw THE METABOLISM OF TUMOURS , 1931 .

[16]  I. Tannock,et al.  Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. , 1997, British Journal of Cancer.

[17]  J. Griffiths,et al.  Causes and consequences of acidic pH in tumors: a magnetic resonance study. , 1999, Advances in enzyme regulation.

[18]  K. Jeong,et al.  Metabolic consequences of a reversed pH gradient in rat tumors. , 1994, Cancer research.

[19]  G. Semenza,et al.  Structural and functional analysis of hypoxia-inducible factor 1. , 1997, Kidney international.

[20]  L. Gerweck Tumor pH: implications for treatment and novel drug design. , 1998, Seminars in radiation oncology.